Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 527, Issue 1-3, Pages 52-59Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2005.10.015
Keywords
glycine(B) site; N-methyl-D-aspartate receptors; dopamine; schizophrenia; antipsychotic
Categories
Ask authors/readers for more resources
The N-methyl-D-aspartate (NMDA) glutamate receptor possesses an obligatory co-agonist site for D-serine and glycine, named the glycine(B) site. Several clinical trials indicate that glycineB agonists can improve negative and cognitive symptoms of schizophrenia when co-administered with antipsychotics. In the present study we have investigated the effects of glycineB agonists on the endogenous release of dopamine from preparations of rat striatal tissue prisms in static conditions. The glycineB agonists glycine (I mM) and D-serine (10 mu M), but not D-cycloserine (10 mu M), substantially increased the spontaneous release of dopamine, but significantly reduced the release of dopamine evoked by NMDA. The effect of glycine on spontaneous release was abolished by the non-competitive NMDA antagonists 5R,10S-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine (MK-801, 10 mu M) and ifenprodil (5 mu M), but was only partially suppressed by the competitive antagonist 4-(3-phosphonopropyl)-piperazine-2-carboxylic acid (CPP, 10 mu M). The selective inhibitor of the glial glycine transporter GlyT1 N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS, 10 mu M) significantly increased the release of dopamine in an MK-801-sensitive manner. Interestingly, haloperidol (I mu M), but not clozapine (10 mu M), prevented the effects of glycine. This study shows that glycineB modulators can control dopamine release by interacting with a distinctive NMDA receptor subtype with which some typical antipsychotics can interfere. (c) 2005 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available